Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
NEW YORK, May 01, 2017 -- Ember Therapeutics, Inc., (OTCQB:EMBT) a publicly traded company is pleased to announced that it has retained Maxim Group LLC, a leading investment banking securities and investment firm, to provide strategic corporate planning and investment banking services to the company. Maxim will focus on strategies to maximize shareholder value through its full scope of investment banking services.
“We are looking forward to working with Maxim as we map out Ember’s financial, partnership and fund raising strategy. We have a Phase II completed asset in osteoarthritis and several commercial products with significant market potential. Maxim’s strategic influence and investment banking services will be an invaluable asset for Ember moving forward,” said Joseph Hernandez, Ember’s Executive Chairman.
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking firm headquartered in New York. Maxim Group provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales and trading, equity research and prime brokerage services. The investment banking group focuses on middle market and emerging growth companies within the shipping, energy, health care, technology, retail, and business and financial services sectors. The institutional coverage of Maxim Group spans North and South America, Europe and Asia. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc. To learn more about Maxim Group, visit maximgrp.com.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a pharmaceutical company developing targeted therapies for pain, osteoarthritis, regenerative medicine and over the counter products. In particular, Ember Therapeutics, Inc. has several commercial stage products and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
Ember Therapeutics Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Ember Therapeutics’ business and Ember Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact Information: Betty Rose (investors) [email protected]
